NEUROCRINE BIOSCIENCES INC (NBIX) stock intrinsic value fair value estimate & owner earnings analysis

Neurocrine Biosciences is a profitable, fast-growing biopharmaceutical company built around INGREZZA (valbenazine), a treatment for tardive dyskinesia and for chorea associated with Huntington's disease. INGREZZA generated $2.51 billion of the company's $2.86 billion in 2025 revenue (about 88%). A second product, CRENESSITY, launched in late 2024 for a rare adrenal condition called congenital adrenal hyperplasia (CAH), had a strong first full year, reaching $301 million in 2025 sales. Two more candidates are in Phase 3 trials: osavampator for major depression (data expected 2027) and direclidine for schizophrenia. We build our estimate of the cash the business actually generates for owners by starting from operating cash flow, removing the swings caused by working-capital timing and by stock-based compensation (a real cost to shareholders even though it doesn't use cash), and subtracting only the capital spending needed to maintain the current business (spending tied to growth is excluded, since it is optional). Because this figure has been volatile from year to year — boosted in some years by a one-time $70 million charge from retiring old debt (2022) and a one-time $138 million charge from retiring convertible notes (2024), and swung around by large non-cash tax adjustments — we anchor our valuation on the median of the last six years (2020–2025), a period that reflects the company at full commercial scale. That median works out to about $1.94 of owner earnings per share, which is a deliberately conservative starting point; the actual, unadjusted 2025 figure was over three times higher, but a single strong year is not a reliable base for a decade-long estimate. The single most important judgment call in this valuation concerns INGREZZA's patent life. In 2023, Neurocrine settled all patent litigation with the generic drug makers that had challenged its patents. Under those settlements, generic versions of INGREZZA cannot enter the U.S. market before March 1, 2038 (a bit earlier is possible under limited circumstances), even though some of the underlying patents run as late as 2040. That gives INGREZZA roughly twelve more years of protected sales — comfortably beyond our ten-year forecast window, but a hard wall the business must be judged against. We have explicitly modeled this: our forecast assumes solid, moderating growth through 2035 as INGREZZA matures, CRENESSITY continues to scale, and osavampator (if successful) reaches the market around 2029–2030, followed by a sharp step-down in INGREZZA sales once generics arrive in 2038, with the company's owner earnings settling at a lower, flat level afterward built around CRENESSITY, the pipeline, and whatever INGREZZA revenue survives brand loyalty. We deliberately did not assume growth continues forever past that point — a single dominant product going generic doesn't get a permanent free pass, and the newer products so far don't have the same scale. Our base case assumes: INGREZZA keeps growing at a high-single-digit to low-double-digit pace for several more years before flattening out; CRENESSITY continues its strong launch trajectory toward roughly $900 million-$1 billion in annual sales; osavampator succeeds and becomes a meaningful contributor from 2029–2030; and profitability continues to improve as the company's commercial infrastructure, already built, is spread across more products. Discounting this path at a flat 6% (the same rate we use for every company we value, so it reflects the cash itself rather than a market view of risk) and applying the 2038 patent cliff as described, we get a value of roughly $170 per share. Our bear case (roughly a one-in-ten outcome) assumes osavampator and direclidine both fail or are not competitive enough to launch, CRENESSITY's growth disappoints as the eligible patient population proves smaller than hoped, INGREZZA's growth is slowed by insurance and pricing pressure, and generic competition arrives closer to the earliest allowed date rather than 2038. In this scenario, the shares are worth around $68 — still positive, because INGREZZA alone throws off substantial cash even in a difficult environment, but a large step down from the base case. Our bull case (roughly a one-in-ten outcome on the upside) assumes both osavampator and direclidine succeed and become substantial products in their own right, CRENESSITY expands further (including internationally), INGREZZA's growth holds up longer than expected, and the eventual arrival of generic competition erodes sales more gradually than a sudden cliff (multiple generic entrants at once doesn't necessarily mean instant, complete substitution, especially in a psychiatric-drug population where physicians are often cautious about switching). Under this case the shares could be worth around $399. Because the gap between our bear and base cases is fairly wide (bear is about 40% of base), reflecting genuine binary risk around clinical trial readouts and the ultimate severity of generic erosion, the margin-of-safety price sits at a substantial discount to our base-case estimate, at around $99 per share, roughly 42% below our base-case value. That is not a comment on where the stock trades today; it is simply our estimate of the price at which these risks are adequately reflected. A few things worth noting plainly: the company appears to carry little to no debt today (it repaid its remaining convertible notes during 2025), so balance-sheet leverage is not a meaningful risk factor here, unlike for many other companies we value. We also note that a meaningful share of our estimated value (over 40% in the base case, more than half in the bull case) comes from what the business is likely to be worth more than a decade from now, after INGREZZA's exclusivity ends — which is inherent to valuing a company whose flagship product still has over a decade of protected life left, but it does mean the estimate rests partly on judgment about a period that is naturally harder to see clearly. Finally, the company's own reported cash flow includes some sizeable, lumpy non-cash items (deferred tax adjustments, one-time debt charges) that we've treated as real but non-recurring; we're confident in how we've handled them, but flag them because they explain why the year-to-year earnings power we calculated bounces around more than the underlying business does.